Efficacy of antimicrobial coating suture coated polyglactin 910 with tricosan (Vicryl plus) compared with polyglactin 910 (Vicryl) in reduced surgical site infection of appendicitis, double blind randomized control trial, preliminary safety report.
OBJECTIVE
To evaluate the efficacy and safety of new antibacterial suture (Vicryl Plus) compared with a traditional braided suture (Vicryl) in a clinical study. The primary goal was to study effectiveness on reduced surgical site infection in an appendectomy operation. The authors' secondary goal was to analyze the safety and physical properties of Vicryl plus.


METHODS
This was a prospective, randomized, controlled, double blind, comparative, single-center study. After appendectomy was done, the patients were randomized in two groups: Vicryl Plus and Vicryl to selected suture for suturing the abdominal sheath. The surgical site infection was evaluated for 30 days, 6 months, and 1 year. The surgeons and attending doctor were blind to the type of suture. This is the primary report of the first 100 patients.


RESULTS
There was no difference in demographic and preoperative clinical in both groups. Although there was no statistical difference in the surgical site infection of Vicryl and Vicryl Plus (8 and 10%, p = 0.05), one case of deep surgical site infection was detected in the Vicryl group. No complications and no difference in related suture materials were detected.


CONCLUSIONS
Coated polyglactin 910 with tricosan (Vicryl Plus) is safe and satisfactory in surgical practice. Surgical site infection of appendectomy seemed too to be comparable between coated polyglactin 910 with tricosan (Vicryl Plus) and traditional polyglactin 910 (Vicryl) group.
Mingmalairak
Chatchai
C
Department of Surgery, Faculty of Medicine, Thammasat University, Pathumthani, Thailand. chatchaiming@yahoo.com
Ungbhakorn
Pookate
P
Paocharoen
Veeraya
V
D000293:Adolescent; D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001064:Appendicitis / Q000188:drug therapy / Q000601:surgery*; D001065:Appendix / Q000382:microbiology / Q000601:surgery; D020099:Coated Materials, Biocompatible; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011098:Polyglactin 910 / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D013530:Surgical Wound Infection / Q000517:prevention & control*; D013537:Sutures; D016896:Treatment Outcome; D014260:Triclosan / Q000008:administration & dosage / Q000627:therapeutic use*; D055815:Young Adult
D000890:Anti-Infective Agents; D020099:Coated Materials, Biocompatible; D011098:Polyglactin 910; D014260:Triclosan